Dopamine receptor D3

Last updated

DRD3
3PBL (D3).png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases DRD3 , D3DR, ETM1, FET1, dopamine receptor D3
External IDs OMIM: 126451; MGI: 94925; HomoloGene: 623; GeneCards: DRD3; OMA:DRD3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_007877

RefSeq (protein)

NP_000787
NP_001269492
NP_001277738
NP_387512

NP_031903

Location (UCSC) Chr 3: 114.13 – 114.2 Mb Chr 16: 43.57 – 43.64 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Dopamine receptor D3 (DRD3) is a protein belonging to the dopamine receptor family of G protein-coupled receptors. In humans, it is encoded by the DRD3 gene located on chromosome 3q13.3. [5] [6]

Contents

Signaling

The D3 receptor belongs to the D2-like receptor subfamily, which also includes D2 and D4 receptors. It couples primarily to Gi/Go proteins, leading to inhibition of adenylyl cyclase and reduced intracellular cAMP levels. [7]

The D3 receptor displays the highest binding affinity for dopamine among dopamine receptor subtypes, making it a key regulator of tonic dopamine signaling. [8]

Expression

D3 receptors are primarily expressed in limbic brain regions such as the nucleus accumbens, islands of Calleja, and olfactory tubercle. Their distribution in phylogenetically older brain areas suggests an important role in emotion, motivation, and cognition. [9]

Function

Activation of the D3 receptor regulates dopamine release and modulates neuronal excitability. Preclinical and clinical studies implicate it in:

Genetic polymorphisms

The DRD3 Ser9Gly polymorphism (rs6280) alters receptor binding characteristics and has been studied in relation to:

Pharmacology

D3 ligands include:

Many of these ligands are used clinically in Parkinson’s disease or schizophrenia, while others remain experimental.

Protein interactions

The D3 receptor has been shown to interact with:

Clinical significance

See also

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000151577 Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000022705 Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Le Coniat M, Sokoloff P, Hillion J, Martres MP, Giros B, Pilon C, et al. (September 1991). "Chromosomal localization of the human D3 dopamine receptor gene". Human Genetics. 87 (5): 618–620. doi:10.1007/bf00209024. PMID   1916765. S2CID   28411786.
  6. "Entrez Gene: DRD3 dopamine receptor D3".
  7. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews. 78 (1): 189–225. doi:10.1152/physrev.1998.78.1.189. PMID   9457173.
  8. Robinson SW, Jarvie KR, Caron MG (August 1994). "High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains". Molecular Pharmacology. 46 (2): 352–356. doi:10.1016/S0026-895X(25)09690-7. PMID   7915820.
  9. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (September 1990). "Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics". Nature. 347 (6289): 146–151. doi:10.1038/347146a0. PMID   1975644.
  10. Favier M, Carcenac C, Savasta M, Carnicella S (2022). "Dopamine D3 Receptors: A Potential Target to Treat Motivational Deficits in Parkinson's Disease". Current Topics in Behavioral Neurosciences. Vol. 60. Berlin, Heidelberg: Springer. pp. 109–132. doi:10.1007/7854_2022_316. ISBN   978-3-031-23057-8. PMID   35469394.
  11. Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, et al. (August 2009). "Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats". European Journal of Pharmacology. 616 (1–3): 134–140. doi:10.1016/j.ejphar.2009.06.029. PMID   19549514.
  12. Xi ZX, Gardner EL (2007). "Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction". CNS Drug Reviews. 13 (2): 240–259. doi:10.1111/j.1527-3458.2007.00013.x. PMC   3771110 . PMID   17627675.
  13. Zhi Y, Yuan Y, Si Q, Wang M, Shen Y, Wang L, et al. (2019). "The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson's Disease". Parkinson's Disease. 2019: 1642087. doi: 10.1155/2019/1642087 . PMC   6501220 . PMID   31143436.
  14. Krishnamoorthy S, Rajan R, Banerjee M, Kumar H, Sarma G, Krishnan S, et al. (September 2016). "Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients". Parkinsonism & Related Disorders. 30: 13–17. doi:10.1016/j.parkreldis.2016.06.005. PMID   27325396.
  15. Griffon N, Jeanneteau F, Prieur F, Diaz J, Sokoloff P (September 2003). "CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors". Brain Research. Molecular Brain Research. 117 (1): 47–57. doi:10.1016/S0169-328X(03)00283-3. PMID   14499480.
  16. Binda AV, Kabbani N, Lin R, Levenson R (September 2002). "D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N". Molecular Pharmacology. 62 (3): 507–513. doi:10.1124/mol.62.3.507. PMID   12181426.